Paweł Ziemiański1, Wojciech Lisik1, Rafał J Marszałek1, Tomasz Cieciura2, Justyna Domienik-Karłowicz3, Janusz Trzebicki4, Tomasz Gryczewski1, Zbigniew Wierzbicki1, Maciej Kosieradzki1, Magdalena Durlik5, Piotr Pruszczyk3, Andrzej Chmura1. 1. Department of General Surgery and Transplantology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland. 2. Department of Immunology, Transplantology and Internal Diseases, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland. 3. Department of Internal Diseases and Cardiology, Medical University of Warsaw, Warsaw, Poland. 4. 1st Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland. 5. Department of Transplant Medicine and Nephrology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.
Abstract
BACKGROUND: Transplantation is the best and approved method of renal replacement therapy. Graft function depends not only on proper regulation of immune processes but also on the optimal control of chronic diseases. The obesity epidemic involves the healthy population and organ recipients equally. Obesity and metabolic syndrome lead to a number of disorders exerting adverse effects on the transplanted organ. CASE REPORT: We report a case of a kidney recipient, 12 years after transplantation, with chronic graft failure (serum creatinine level 2.1 mg/dl, GFR 31 ml/min/1.73 m(2)), morbid obesity (weight 139.8 kg, BMI 46.2 kg/m(2), excess body mass 73.1 kg), hypertension, poorly controlled type 1 diabetes (HbA1c 8.8%), and ischemic heart disease. The cause of chronic kidney disease was diabetic nephropathy. The patient was the first Polish kidney recipient referred for bariatric gastric bypass surgery (GB). Directly after surgery, transient creatinine elevation (4.7 mg/dl) was noted. There was no reduction in diuresis. Desired weight loss was achieved within 12 months after surgery (body mass 81.9, BMI 27.1 kg/m(2), percentage loss of excess weight 86.9%) with improved graft function (serum creatinine level 1.3 mg/dl, GFR 45.1 ml/min/1.73 m(2)) and reduction of daily insulin requirement from 74 to 40 units. The severity of hypertension and ischemic heart disease diminished as well. CONCLUSIONS: Metabolic surgery is the best treatment of obesity and may contribute to post-transplantation care if weight gain is observed, as a result of the interaction of many factors leading to deterioration of renal graft function.
BACKGROUND: Transplantation is the best and approved method of renal replacement therapy. Graft function depends not only on proper regulation of immune processes but also on the optimal control of chronic diseases. The obesity epidemic involves the healthy population and organ recipients equally. Obesity and metabolic syndrome lead to a number of disorders exerting adverse effects on the transplanted organ. CASE REPORT: We report a case of a kidney recipient, 12 years after transplantation, with chronic graft failure (serum creatinine level 2.1 mg/dl, GFR 31 ml/min/1.73 m(2)), morbid obesity (weight 139.8 kg, BMI 46.2 kg/m(2), excess body mass 73.1 kg), hypertension, poorly controlled type 1 diabetes (HbA1c 8.8%), and ischemic heart disease. The cause of chronic kidney disease was diabetic nephropathy. The patient was the first Polish kidney recipient referred for bariatric gastric bypass surgery (GB). Directly after surgery, transient creatinine elevation (4.7 mg/dl) was noted. There was no reduction in diuresis. Desired weight loss was achieved within 12 months after surgery (body mass 81.9, BMI 27.1 kg/m(2), percentage loss of excess weight 86.9%) with improved graft function (serum creatinine level 1.3 mg/dl, GFR 45.1 ml/min/1.73 m(2)) and reduction of daily insulin requirement from 74 to 40 units. The severity of hypertension and ischemic heart disease diminished as well. CONCLUSIONS: Metabolic surgery is the best treatment of obesity and may contribute to post-transplantation care if weight gain is observed, as a result of the interaction of many factors leading to deterioration of renal graft function.
Authors: John R Montgomery; Jordan A Cohen; Craig S Brown; Kyle H Sheetz; Grace F Chao; Seth A Waits; Dana A Telem Journal: Am J Transplant Date: 2020-05-08 Impact factor: 8.086
Authors: Kamal K Mahawar; Nimantha De Alwis; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: John P Kirwan; Ali Aminian; Sangeeta R Kashyap; Bartolome Burguera; Stacy A Brethauer; Philip R Schauer Journal: Diabetes Care Date: 2016-06 Impact factor: 19.112
Authors: Alexandra Chow; Noah J Switzer; Jerry Dang; Xinzhe Shi; Christopher de Gara; Daniel W Birch; Richdeep S Gill; Shahzeer Karmali Journal: J Obes Date: 2016-06-08